The BALANCE Model: the plan behind the Bridge
Published by GLP-1 Coverage Guide · Updated · No clinician review is credited for this page.
Short answer: BALANCE was a proposed model to temporary GLP-1 coverage: a model letting Part D plans voluntarily cover weight-loss GLP-1s starting in 2027. Its Medicare component was postponed indefinitely in April 2026 ; CMS says its Medicare component is not launching in 2027 — and the Bridge was extended through 2027 as the stopgap. Understanding BALANCE is understanding why the Bridge exists and why its future is genuinely uncertain.
Sources for the coverage rules are listed below. An update date marks a revision; it does not imply a sitewide medical review.
What BALANCE was, and why plans balked
The design: rather than mandating coverage, CMS invited Part D plans to opt in to covering GLP-1s for obesity, with the model testing effects on costs and outcomes across Medicare and Medicaid. The failure mode: participation was voluntary, and too few plans signed up — CMS's own threshold (80% plan participation) wasn't met, and the Medicare component was shelved for 2027. Plans' hesitance wasn't mysterious: GLP-1s are expensive, the eligible population is enormous, and a plan that covered them generously feared attracting exactly the costliest enrollees — the classic adverse-selection problem.
What it means going forward: the voluntary-participation approach has now demonstrably struggled once. A future attempt likely needs different economics — cheaper drugs, reinsurance for plans, or a mandate — which is why the Bridge's fate connects to larger drug-pricing currents, not just one program decision.
Take the Medicare eligibility check →
Common questions
Is BALANCE dead or delayed?
The Medicare component was postponed indefinitely rather than formally cancelled; the distinction matters little in practice until CMS announces something new. Our extension tracker follows it.
Did any part of BALANCE proceed?
The model as announced spanned Medicare and Medicaid components on separate tracks. For the Medicare side — what determines Bridge patients' future — the answer is no; check our tracker for current status of the rest.
Why didn't CMS just mandate plan coverage?
A mandate has budget and statutory implications far beyond a voluntary demonstration — historically, the statute itself excluded weight-loss drugs from Part D, which is the wall all these workarounds are built against.